GANX
GANX
NASDAQ · Biotechnology

Gain Therapeutics Inc

$2.01
+0.07 (+3.61%)
As of Apr 1, 3:25 PM ET ·
Financial Highlights (FY 2025)
Revenue
11.43M
Net Income
-2,402,162
Gross Margin
51.4%
Profit Margin
-21.0%
Rev Growth
+22.4%
D/E Ratio
1.10
Revenue & Net Income
Margin Trends
FY 2025 FY 2024 FY 2023
Gross Margin 51.4% 51.4% 51.4%
Operating Margin -23.7% -24.8% -23.4%
Profit Margin -21.0% -18.1% -20.7%
Income Statement
FY 2025 FY 2024 FY 2023
Revenue 11.43M 10.74M 10.31M
Gross Profit 5.87M 5.52M 5.30M
Operating Income -2,713,505 -2,662,093 -2,409,190
Net Income -2,402,162 -1,945,366 -2,138,218
Gross Margin 51.4% 51.4% 51.4%
Operating Margin -23.7% -24.8% -23.4%
Profit Margin -21.0% -18.1% -20.7%
Rev Growth +22.4% -6.0% +21.1%
Balance Sheet
FY 2025 FY 2024 FY 2023
Total Debt 28.77M 29.36M 24.76M
Total Equity 26.08M 22.63M 21.54M
D/E Ratio 1.10 1.30 1.15
Cash Flow
FY 2025 FY 2024 FY 2023
EBITDA -3,961,862 -3,629,854 -3,514,676
Free Cash Flow -2,281,552 -2,429,555 -1,597,015